EBMT 2022 | Future perspectives in FMT for the treatment of GvHD

Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, talks on the future of fecal microbiota transplantation (FMT) for graft-versus-host disease (GvHD). To date, most studies have evaluated FMT in patients with steroid-refractory acute GvHD (SR-aGvHD), which is a population with a high mortality rate and who have been exposed to several treatments. According to Dr Shouval, the use of FMT should shift towards prevention of GvHD in the future. In addition, it will be interesting to evaluate the efficacy of FMT in combination with other treatments. To assess the utility of FMT for the prevention and treatment of GvHD, it will be important to standardize the processes for preparing and administering FMT, as well as to conduct randomized controlled clinical trials. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.